Combination approaches with immune checkpoint blockade in cancer therapy
In healthy individuals, immune checkpoint molecules prevent autoimmune responses and limit immune cell-mediated tissue damage. Tumors frequently exploit these molecules to evade eradication by the immune system. Over the past years, immune checkpoint blockade of cytotoxic T lymphocyte antigen-4 (CTL...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2016-11-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2016.00233/full |
| _version_ | 1811312158468734976 |
|---|---|
| author | Maarten Swart Inge Verbrugge Joost Beltman |
| author_facet | Maarten Swart Inge Verbrugge Joost Beltman |
| author_sort | Maarten Swart |
| collection | DOAJ |
| description | In healthy individuals, immune checkpoint molecules prevent autoimmune responses and limit immune cell-mediated tissue damage. Tumors frequently exploit these molecules to evade eradication by the immune system. Over the past years, immune checkpoint blockade of cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) emerged as promising strategies to activate anti-tumor cytotoxic T cell responses. Although complete regression and long-term survival is achieved in some patients, not all patients respond. This review describes promising, novel combination approaches involving immune checkpoint blockade, aimed at increasing response-rates to the single treatments. |
| first_indexed | 2024-04-13T10:32:23Z |
| format | Article |
| id | doaj.art-04591dfbdfa44cd49f28f1a5de9d62cd |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-13T10:32:23Z |
| publishDate | 2016-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-04591dfbdfa44cd49f28f1a5de9d62cd2022-12-22T02:50:09ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2016-11-01610.3389/fonc.2016.00233226404Combination approaches with immune checkpoint blockade in cancer therapyMaarten Swart0Inge Verbrugge1Joost Beltman2Leiden UniversityNetherlands Cancer InstituteLeiden UniversityIn healthy individuals, immune checkpoint molecules prevent autoimmune responses and limit immune cell-mediated tissue damage. Tumors frequently exploit these molecules to evade eradication by the immune system. Over the past years, immune checkpoint blockade of cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) emerged as promising strategies to activate anti-tumor cytotoxic T cell responses. Although complete regression and long-term survival is achieved in some patients, not all patients respond. This review describes promising, novel combination approaches involving immune checkpoint blockade, aimed at increasing response-rates to the single treatments.http://journal.frontiersin.org/Journal/10.3389/fonc.2016.00233/fullCTLA-4cancer immunotherapyPD-1Combination therapiesimmune checkpoint inhibitors |
| spellingShingle | Maarten Swart Inge Verbrugge Joost Beltman Combination approaches with immune checkpoint blockade in cancer therapy Frontiers in Oncology CTLA-4 cancer immunotherapy PD-1 Combination therapies immune checkpoint inhibitors |
| title | Combination approaches with immune checkpoint blockade in cancer therapy |
| title_full | Combination approaches with immune checkpoint blockade in cancer therapy |
| title_fullStr | Combination approaches with immune checkpoint blockade in cancer therapy |
| title_full_unstemmed | Combination approaches with immune checkpoint blockade in cancer therapy |
| title_short | Combination approaches with immune checkpoint blockade in cancer therapy |
| title_sort | combination approaches with immune checkpoint blockade in cancer therapy |
| topic | CTLA-4 cancer immunotherapy PD-1 Combination therapies immune checkpoint inhibitors |
| url | http://journal.frontiersin.org/Journal/10.3389/fonc.2016.00233/full |
| work_keys_str_mv | AT maartenswart combinationapproacheswithimmunecheckpointblockadeincancertherapy AT ingeverbrugge combinationapproacheswithimmunecheckpointblockadeincancertherapy AT joostbeltman combinationapproacheswithimmunecheckpointblockadeincancertherapy |